Scrip Symbol

CIPLA (NSE)

Key Financial Performance

Revenue: ₹7,404 crore for Q2 FY27, representing 4% sequential growth quarter-on-quarter.

EBITDA Margin: 18.7% (excluding other income), showing a sequential improvement of 200 basis points.

Gross Margin: 64.4% after material costs, up 7% quarter-on-quarter, supported by improved product mix.

Total Expenses: ₹3,382 crores, reflecting a 4% quarter-on-quarter increase due to planned investments in upcoming product launches and enhanced manufacturing readiness.

R&D Investment: ₹423 crores (5.7% of revenue), focused on product filing and key development programs. Full-year R&D expense guidance maintained at 6-7% of revenue.

Profit After Tax: ₹878 crores, representing 11.9% of sales with sequential improvement of 77 basis points.

Effective Tax Rate: 27.2% for the quarter.

Cash Position: Net cash equivalent balance of ₹9,823 crores as of 30th September 2026, with debt including lease liabilities at ₹699 crores.

Business Segment Performance

One India Business:

  • Recorded highest-ever quarterly revenue with 12% YoY growth
  • Branded prescription business grew 15% YoY, outperforming the market
  • Chronic portfolio mix stood at 60.3% (IQVIA MAT September 2026)
  • Key therapy growth rates: Respiratory 11%, Antidiabetes 50% (including GLP-1), Urology 11%, Dermatology 16%
  • Trade generics business delivered strong double-digit QoQ growth
  • Consumer Health business showed upward trajectory with Nicotex, Omnigel and Cipladine maintaining leadership positions

North America Business:

  • Revenue of $172 million in Q2, representing $10 million improvement versus previous quarter
  • Maintains #1 position in US Albuterol MDI market with 22% market share (IQVIA data for last week of September 2026)
  • Received approvals for generic Ventolin (Q1) and generic Advair DPI (Q2)

South Africa Private Market:

  • Achieved strong secondary growth of 6.5%, outperforming market growth of 5% (IQVIA MAT August 2026)

EMEU Business:

  • Revenue of $101 million during the quarter despite challenging geopolitical environment

Strategic Developments and Pipeline Updates

Product Approvals:

  • Received FDA approval for generic Advair DPI in Q2 FY27 (first DPI approval from US-based manufacturing network)
  • Generic Ventolin approved in Q1 FY27

Partnerships:

  • Exclusive partnership with Qilu Pharmaceutical for US commercialization of biosimilar to Keytruda (Pembrolizumab)
  • Exclusive licensing agreement with CTTQ, SinoBiopharma Group for novel HER2 bispecific antibody drug conjugate

Pipeline Guidance:

  • 3 additional significant launches planned for US in FY27: two respiratory assets and one key peptide opportunity
  • Four biosimilar programs under development for global markets
  • 45-50 filings planned over next 3 years for North America market
  • Biosimilar Pembrolizumab expected to be among first wave of launches targeting 2029 patent expiry

New Launches (India):

  • Revesmart (respiratory)
  • Galvus DM and SR (antidiabetes)
  • Dytor E (cardiovascular)
  • Rizontem (anti-infectives)

Regulatory and Manufacturing Updates

US FDA Inspections:

  • Invagen Unit 3 facility in New York classified as Voluntary Action Indicated (VAI)
  • Invagen manufacturing facility in Long Island, New York received routine GMP inspection with 0 Form 483 observations
  • Pithampur facility in India received follow-up GMP inspection with 7 observations in Form 483
  • Company continues to engage constructively with US FDA on remediation

Manufacturing Strategy:

  • New product approvals mitigated through US sites or Goa facility
  • No anticipated downsides from Indore audit

Guidance and Outlook

North America: Maintain guidance to exit FY27 with $1 billion annualized revenue run rate

EBITDA Margin: Full-year guidance maintained at 18.5-20% with expected sequential improvement in remaining quarters

R&D Expenditure: Full-year guidance maintained at 6-7% of revenue

Tax Rate: Expected to be in range of 27-27.5% for full year

Capital Allocation

Company maintains strong net cash position of ₹9,823 crores and is evaluating opportunities to acquire complex or differentiated assets, primarily in North America or Europe markets.